ArticleClinical and translational medicine2025
Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition.
Ngar Woon Kam et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.